

These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

| Company Name | Business Partner | Drug Name | Generic Name | Unique ID | Studied Indications or Disease | Phase |
|------------------------|--|-----------|--------------|-----------|--------------------------------|-----------|
| Abbott Laboratories | | Humira | Adalimumab | M04-691 | Crohns Disease | Phase III |
| Clinical Study Summary | Protocol No. M04-691: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response or are Intolerant to Infliximab | | | | | |

Abbott Laboratories (Abbott) will use reasonable efforts to include accurate and up-to-date information, consistent with Abbott policies and procedures, on the ClinicalStudyResults.org web site. However, because, among other reasons, the status of studies often changes, Abbott can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. Persons accessing and using information posted by Abbott on the ClinicalStudyResults.org web site do so at their own risk. Abbott disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Abbott shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Abbott on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof.